Exabis Library
Welcome to the e-CCO Library!
DOP10: Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP10: Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP10: Serum N-glycomic biomarkers predict treatment escalation in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP11 Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP11: A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP11: A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP11: Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP11: Early intestinal ultrasound predicts endoscopic response to anti-inflammatory treatment and shows drug-specific response to biologicals and tofacitinib in Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP11: Fibrosis and MAGNIFI-CD activity-index at MRI to predict treatment outcome in perianal fistulising Crohn’s Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP11: Lymphocyte activation gene (LAG)-3 on T cells is a potential therapeutic target in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP11: Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn's Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP11: Normalisation of faecal calprotectin within 12 months of diagnosis is associated with a reduced risk of disease progression in Crohn's Disease
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP12 Efficacy of ustekinumab for ulcerative colitis through 2 years: Results of the UNIFI maintenance study and long-term extension
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP12: Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP12: Mutations in the X-linked inhibitor of apoptosis protein promote susceptibility to microbiota-induced intestinal inflammation
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP12: Non-invasive assessment of intestinal inflammatory activity in Ulcerative Colitis by Multispectral Optoacoustic Tomography (MSOT)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP12: Validation of a modified simple ultrasound activity Score for children with Crohn’s Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP12: Validation of radiomics features on MR enterography characterizing inflammation and fibrosis in stricturing Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP12: Validation of radiomics features on MR enterography characterizing inflammation and fibrosis in stricturing Crohn’s disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM